Argent BioPharma Limited (H5O0)
XDUS 
Summary
H5O0 Chart
People also search for
Argent BioPharma Limited (H5O0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Argent BioPharma Limited ever had a stock split?
Argent BioPharma Limited Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Roby Reuven Zomer CEO | XDUS Exchange | AU000000MXC6 ISIN |
| AU Country | - Employees | - Last Dividend | 30 Oct 2023 Last Split | - IPO Date |
Overview
Argent BioPharma Limited is a clinical-stage biopharmaceutical company engaged in the discovery and development of medicines with a focus on immunology and neurology. Operating globally, the company has made strides in the development of therapeutic candidates aimed at addressing significant medical conditions. Initially known as MGC Pharmaceuticals Limited, the company underwent a rebranding to Argent BioPharma Limited, marking a new chapter in its mission to advance healthcare. Founded in 2014 and headquartered in Subiaco, Australia, Argent BioPharma is committed to innovating at the frontier of medical research, bearing the promise of delivering transformative treatments to patients worldwide.
Products and Services
- CimetrA:
Currently in phase II clinical trial, CimetrA is being developed as a promising therapeutic option for SLE Lupus, offering anti-inflammatory benefits, and is also being tested for its efficacy against SARS COVID-19. This product candidate exemplifies Argent BioPharma’s dedication to tackling both chronic autoimmune disorders and emergent infectious diseases.
- CannEpil:
In the phase I clinical trial stage, CannEpil targets refractory epilepsy and cerebral palsy. This innovative product is aimed at improving the quality of life for individuals dealing with these challenging neurological conditions, demonstrating Argent BioPharma's commitment to neurology and patient care.
- CogniCann:
Also in phase I clinical trials, CogniCann is designed for the symptomatic relief of Dementia and Alzheimer's disease. Through this candidate, Argent BioPharma is addressing significant needs in geriatric care and neurodegenerative disorder management, reflecting its forward-looking approach to healthcare solutions.
- Irnican:
Argent BioPharma offers Irnican for the treatment of brain cancer, indicating a broader oncological interest within the company’s portfolio. The endeavor to provide options for such a critical area of medicine underscores the company's comprehensive approach to improving patient outcomes through innovation.
